Matches in Wikidata for { <http://www.wikidata.org/entity/Q102153514> ?p ?o ?g. }
Showing items 1 to 37 of
37
with 100 items per page.
- Q102153514 description "clinical trial" @default.
- Q102153514 description "ensayo clínico" @default.
- Q102153514 description "ensayu clínicu" @default.
- Q102153514 description "klinisch onderzoek" @default.
- Q102153514 description "клінічне випробування" @default.
- Q102153514 description "临床试验" @default.
- Q102153514 name "Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19" @default.
- Q102153514 name "Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19" @default.
- Q102153514 type Item @default.
- Q102153514 label "Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19" @default.
- Q102153514 label "Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19" @default.
- Q102153514 prefLabel "Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19" @default.
- Q102153514 prefLabel "Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19" @default.
- Q102153514 P1050 Q102153514-1B081FB6-EBDE-4EA9-B0A8-77A47C80C751 @default.
- Q102153514 P1132 Q102153514-8F2C8B03-5624-449D-83E3-87EF50A225F8 @default.
- Q102153514 P1476 Q102153514-98C2F39B-2DD1-4823-9B24-C84156945EE4 @default.
- Q102153514 P17 Q102153514-5619B994-AD82-462C-B900-BB99F3C60D06 @default.
- Q102153514 P2899 Q102153514-89D14161-7BAB-47CD-AC29-C3E5BCCA655D @default.
- Q102153514 P3098 Q102153514-20AFB239-6C84-43DE-897D-028F2752B28E @default.
- Q102153514 P31 Q102153514-38ABDA09-A68B-46FF-A7DC-D8E57E0591DA @default.
- Q102153514 P580 Q102153514-F6CC5CC7-AF5B-46B6-9EEB-4EAF96DE3CCB @default.
- Q102153514 P582 Q102153514-A8A82D66-F548-42CF-B1B8-DD5BD890E2D4 @default.
- Q102153514 P6099 Q102153514-8665F1D5-EA00-4D47-8867-A50C2980D3F1 @default.
- Q102153514 P8005 Q102153514-D85A5EC2-D8FA-478B-8C2B-2888D41C8E01 @default.
- Q102153514 P8363 Q102153514-A80A54F9-9ADD-4C80-B1E4-952EAE495726 @default.
- Q102153514 P1050 Q179630 @default.
- Q102153514 P1132 "+36" @default.
- Q102153514 P1476 "A Randomized, Double-blind, Dose-ranging, Placebo Controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19 (INTEGRIS-ARDS)" @default.
- Q102153514 P17 Q30 @default.
- Q102153514 P2899 "+18" @default.
- Q102153514 P3098 "NCT04565249" @default.
- Q102153514 P31 Q30612 @default.
- Q102153514 P580 "2020-10-22T00:00:00Z" @default.
- Q102153514 P582 "2021-08-31T00:00:00Z" @default.
- Q102153514 P6099 Q42824440 @default.
- Q102153514 P8005 Q76649708 @default.
- Q102153514 P8363 Q78089383 @default.